Cargando…
GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma
Glioblastoma multiforme (GBM) is the most aggressive malignant primary brain tumor of the central nervous system. Despite continuous progression in treatment options for GBM like surgery, radiotherapy, and chemotherapy, this disease still has a high rate of recurrence. The endoplasmic reticulum (ER)...
Autores principales: | Zhang, Xu, Wu, Runqiu, Tian, Cong, Wang, Wanzhou, Zhou, Lingni, Guo, Tongxuan, Yu, Jiefeng, Wu, Changyong, Shen, Yang, Liu, Xuejiao, Yu, Rutong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960808/ https://www.ncbi.nlm.nih.gov/pubmed/35347123 http://dx.doi.org/10.1038/s41420-022-00950-5 |
Ejemplares similares
-
GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death
por: Liu, Guanzheng, et al.
Publicado: (2021) -
UBA1 inhibition contributes radiosensitization of glioblastoma cells via blocking DNA damage repair
por: Wu, Changyong, et al.
Publicado: (2023) -
Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment
por: Guo, Tongxuan, et al.
Publicado: (2023) -
Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
por: Majeed, Safa, et al.
Publicado: (2022) -
GRP78 in lung cancer
por: Xia, Shengkai, et al.
Publicado: (2021)